Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from ecancermedicalscience

12:36 EST 21st February 2018 | BioPortfolio

Here are the most relevant search results for "ecancermedicalscience" found in our extensive news archives from over 250 global news sources.

More Information about ecancermedicalscience on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ecancermedicalscience for you to read. Along with our medical data and news we also list ecancermedicalscience Clinical Trials, which are updated daily. BioPortfolio also has a large database of ecancermedicalscience Companies for you to search.

Showing News Articles 1–25 of 1,100+ from ecancermedicalscience

Wednesday 21st February 2018

Local environment plays key role in breast cancer progression

Breast cancer is the most commonly diagnosed cancer in women -- one in eight (12.4 percent) in the U.S. will be diagnosed with it. Invasive breast cancer is dangerous for two reasons: It can aggressively spread to other organs in the body, and it is...

'Icebreaker' protein opens genome for t cell development

Almost all cells in the human body have identical DNA sequences, yet there are 200-plus cell types with different sizes, shapes, and chemical compositions. Determining what parts of the genome are read to make protein and which are silenced is...

Tuesday 20th February 2018

Study weighs risks and benefits of phase I trials in paediatric cancer

On average, 1 in 10 children who enroll in pediatric phase I cancer trials are improved after the trial, and 1 in 50 die from drug-related complications, according to a new systematic review and meta-analysis published this week in PLOS Medicine by...

Optical imaging predicts chemotherapy response

Neoadjuvant chemotherapy is used to treat some women with invasive, but operable, breast cancer. The treatment is given for five to six months before surgery to eliminate active cancer cells. Patients who achieve a complete response have a lower risk of...

'Click chemistry' reactions may boost cancer-fighting drug potency

Researchers at The Scripps Research Institute (TSRI) have developed a quick and easy way to simultaneously modify dozens of drugs or molecules to improve their disease-fighting properties. Using the approach, scientists exchanged one chemical group for...

Monday 19th February 2018

Leading cancer organisations provide guidance on understanding and managing immunotherapy side effects

Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body's immune system to attack cancer, these treatments can send...

US FDA approves durvalumab for unresectable stage III NSCLC

Tthe US Food and Drug Administration (FDA) has approved durvalumab for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation...

Liquid biopsy can help predict outcomes in metastatic triple-negative breast cancer

A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer (TNBC), according to new research published in the Journal of Clinical...

Sunday 18th February 2018

Ras protein's role in spreading cancer

Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein...

Studying mitosis' structure to understand the inside of cancer cells

Cell division is an intricately choreographed ballet of proteins and molecules that divide the cell. During mitosis, microtubule-organizing centers (MTOCs) assemble the spindle fibers that separate the copying chromosomes of DNA. While scientists are...

Friday 16th February 2018

Induced pluripotent stem cells as possible cancer vaccine

Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or disease. Now, a study in mice...

Accurate model of aggressive brain cancer developed

A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers. The collaboration of Prof. Prasad Dhurjati, a chemical engineer who has done extensive computer modeling...

Genes to predict how women respond to ovarian cancer treatment

Research published in Nature Scientific Reports has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy. The research showed that the genes we inherit can have a significant impact on how the body...

Thursday 15th February 2018

New mutation linked to ovarian cancer can be passed down through father

A newly identified mutation, passed down through the X-chromosome, is linked to earlier onset of ovarian cancer in women and prostate cancer in father and sons. Kunle Odunsi, Kevin H. Eng and colleagues at Roswell Park Comprehensive Cancer Center in...

Stem cell vaccine immunises lab mice against multiple cancers

Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses in animals that had tumours...

FDA approves apalutamide for non-metastatic castration-resistant prostate cancer

The U.S. Food and Drug Administration has approved apalutamide for patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). Approval was based on a multicenter, double-blind, clinical trial (SPARTAN, NCT01946204) randomizing 1,207...

NICE recommends lenvatinib for differentiated thyroid cancer

The National Institute for Health and Care Excellence (NICE) has issued its final appraisal decision (FAD) recommending reimbursement of lenvatinib for the treatment of progressive, locally advanced or metastatic, differentiated...

Cutting off cervical cancer's fuel supply stymies tumours

Cancer therapies have improved -- in some cases dramatically -- over the past two decades, but treatment for cervical cancer has remained largely unchanged. All patients receive radiation and chemotherapy, yet despite the aggressive approach, the regimen...

Results of immunotherapy to treat aggressive colon tumours in mouse models

In a short space of time, immunotherapy has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind of therapy. Given this observation, it was...

Wednesday 14th February 2018

Selenium enzyme shows promise as cancer therapy

A study published in Science Translational Medicine shows that small molecules that specifically inhibit an important selenium-containing enzyme may be useful in combating cancer. When researchers at Karolinska Institutet in Sweden treated cancer in mice...

Denosumab non-inferior versus zoledronic acid in delaying time to first on-study skeletal-related event

Amgen today announced results from the Phase 3 ‘482 study, the largest international multiple myeloma trial for the prevention of skeletal-related events ever conducted (n=1,718), were published in The Lancet Oncology. In this study, denosumab...

Biology of hormone-sensitive breast cancer in men mapped

Approximately 100 men per year are diagnosed with breast cancer in the Netherlands, compared to more than 14,000 women. In the vast majority of breast cancers, both in men and women, the tumour is hormone-sensitive. This means that hormones, like...

New SIOG practice review published

The  SIOG practice review on the nutritional management of older adults with gastrointestinal cancers: An International Society of Geriatric Oncology (SIOG) review paper has just been published in the Journal of Geriatric Oncology. Malnutrition is one...

Lower-dose radiation effective, safe for HPV head & neck cancer after induction chemo

Results of the phase II OPTIMA clinical trial indicate that patients with head and neck cancers associated with the human papillomavirus (HPV), including those with advanced nodal disease, can receive substantially lower radiation doses safely and...

Nivolumab immunotherapy safe, feasible during chemoradiation for advanced head and neck cancer

Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced head and neck...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks